Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | FOS | P01100 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48127 | 0.89 | LDHA (0.47) | LDHAPPARGPPARAHIF1APTGS1 | |
| SCHEMBL48164 | 0.84 | ALDH1A1 (0.47) | HTTHIF1AMMP1CYP3A4PTGS1 | |
| SCHEMBL11724490 | 0.82 | LDHA (0.51) | LDHAFOSTTRJUNNR3C1 | |
| SCHEMBL47986 | 0.81 | MAOA (0.44) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL22108987 | 0.78 | LDHA (0.55) | LDHAFOSTTRJUNNR3C1 | |
| SCHEMBL11938336 | 0.77 | CYP4F2 (0.50) | LDHALMNASMN1; SMN2HTTPPARG | |
| SCHEMBL25729047 | 0.77 | PPARG (0.51) | LDHALMNASMN1; SMN2HTTPPARG | |
| SCHEMBL18310127 | 0.76 | CYP3A4 (0.49) | LMNASMN1; SMN2HTTPPARGPPARA | |
| SCHEMBL47915 | 0.75 | LDHA (0.59) | LDHASMN1; SMN2HTTPPARGPPARA | |
| SCHEMBL18310130 | 0.75 | KLKB1 (0.48) | LDHALMNASMN1; SMN2HTTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-1614419-B1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8067406-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-7897594-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1614419-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | RB1, ALDH1A2, NR2E3 | LDHA 2595/4885FOS 2829/4885TTR 1050/4885 |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | LDHA 2595/4885FOS 2829/4885TTR 1050/4885 |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | LDHA 4222/4885FOS 708/4885TTR 2887/4885 |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | LDHA 2595/4885FOS 2829/4885TTR 1050/4885 |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | AHNAK, NGF, PMP22 | LDHA 4222/4885FOS 708/4885TTR 2887/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | LDHA 4222/4885FOS 708/4885TTR 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.